CDD-1802

CDD-1802 is a novel small-molecule selective estrogen receptor degrader (SERD) discovered using a DNA-encoded chemical library (DEL) platform. Developed by researchers at the Baylor College of Medicine, CDD-1802 targets both wild-type and mutant estrogen receptor alpha (ERα) proteins, including the common endocrine-resistance-associated mutations Y537S and D538G. In preclinical studies of ER-positive breast cancer, CDD-1802 dramatically decreases ERα protein levels, reduces downstream signaling markers (such as GREB1, TFF1, c-MYC, E2F1, and survivin), and induces apoptosis (indicated by increased cleaved PARP levels). It is being investigated for the treatment of endocrine-resistant, ER-positive breast cancer.